Optical Genome Mapping in Hematological Malignancies

Recruiting

• Conditions: ALL; MDS; Other Hematologic Malignant Neoplasms

• Registration Number: NCT05009537
• Lead Sponsor: University Hospital, Brest

Brief Summary

Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-08
• Study First Submitted: 2021-08-16
• Study First Submitted QC: 2021-08-16
• Last Update Submitted: 2021-08-16
• Study First Posted: 2021-08-17
• Last Update Posted: 2021-08-17
• Study Start: 2021-09
• Primary Completion: 2022-09
• Study Completion: 2026-09

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Minor/Major Patients
• Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made.
• No objection made or consent given

Exclusion Criteria

• Patients under judicial protection (guardianship, curatorship, ...),
• Refusal to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer	2021-2026	identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH.

Secondary Outcome Measures

Name	Time	Method
identification of new chromosomal abnormalities of clinical relevance.	2021-2026
identification of new chromosomal anomalies involved in oncogenic pathways	2021-2026

Trial Locations

Locations (4)

CHIC, service d'hémato clinique; 🇫🇷 Quimper, France

CHRU de Brest; 🇫🇷 Brest, France

CH Morlaix, service d'hémato clinique; 🇫🇷 Morlaix, France

CH St Brieuc, service d'hémato clinique; 🇫🇷 Saint-Brieuc, France